Acute steatohepatitis, due to extreme metabolic dysregulation, as the first presentation of non-alcoholic fatty liver disease

Georgios Kranidiotis, Angeliki Angelidi, Emmanouel Sevdalis, Thomas-Nikolaos Telios, Alexandra Gougoutsi, Andreas Melidonis
1st Department of Internal Medicine, “Tzaneion” General Hospital, Piraeus, Greece

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a slowly progressive chronic disease, with a high prevalence among obese, dyslipidemic or diabetic people, commonly presented as an asymptomatic mild elevation of serum aminotransferases. We report a patient who experienced an acute form of non-alcoholic steatohepatitis, as the first manifestation of NAFLD, due to exacerbation of pre-existing metabolic disorders by an extremely unhealthy lifestyle. A 50-year-old, obese, diabetic man presented with a one-week history of jaundice and malaise. Analysis revealed elevated liver enzymes, bilirubin, lipids, and glucose. Based on patient’s history, physical examination, laboratory results, and imaging findings, acute non-alcoholic steatohepatitis was established as a diagnosis of exclusion. The patient was started on a low-calorie diet free of carbohydrates and fats, in combination with insulin. A dramatic improvement of clinical and laboratory parameters was observed. In the context of extreme metabolic dysregulation, induced by unhealthy diet, NAFLD may present as an acute steatohepatitis.

Case Report

A 50-year-old man was admitted to our hospital because of a 1-week history of jaundice, fatigue and malaise. On physical examination, the patient was obese, with a body mass index of 37 kg/m², and a waist circumference of 136 cm. His temperature was 36.6°C, blood pressure 160/90 mmHg, and heart rate 107 bpm. Hepatomegaly was detected. The liver was soft, and nontender, with a smooth edge palpable 5 cm below the right costal margin. No xanthomas were found.

The patient’s medical history included type II diabetes mellitus, diagnosed 7 years ago, dyslipidemia (elevated triglycerides, mildly increased cholesterol, and reduced high density lipoprotein - cholesterol), two-vessel coronary artery disease, treated with percutaneous transluminal coronary angioplasty plus stenting 7 months before this admission, and an episode of acute pancreatitis 4 years ago. His family history was notable for gastric cancer in his father.

The patient was an unmarried chandler, who lived with his parents and brother in a working-class suburb of Athens. He had been a heavy smoker (approximately 115 pack-years), while consumed only small quantities of alcohol during social events (<100 g per week). He reported no use of illicit drugs or anabolic steroids, no ingestion of mushrooms, herbal preparations or nutritional supplements, and no exposure to environmental toxins. He was following an extremely unhealthy dietary pattern, characterized by exorbitant calorie intake (estimated amount of 8000 kcal per day), and excessive consumption of saturated animal fats and simple carbohydrates, combined with a sedentary lifestyle and lack of physical activity. His daily medication regimen included aspirin, nebivolol, enalapril, metformin, vildagliptin, and omega-3 fatty acids [eicosapentaenoic (EPA), and docosahexaenoic acid (DHA)].

The most prominent laboratory abnormalities were conjugated hyperbilirubinemia (total bilirubin 10 mg/dL, direct bilirubin 6.6 mg/dL), elevation of liver enzymes, with a disproportionate rise of aminotransferases in comparison to alkaline phosphatase (aspartate transaminase 474 U/L, alanine transaminase 647 U/L, gamma-glutamyltransferase >1453 U/L, alkaline phosphatase 409 U/L), and striking hypertriglyceridemia (triglycerides >1420 mg/dL). The glycosylated hemoglobin value of 11.1% indicated poor diabetic control.

Conclusion

...
Case Report

The initial step in the evaluation of a jaundiced patient with conjugated hyperbilirubinemia accompanied by other liver test abnormalities is to differentiate between a hepatocellular and a cholestatic process. In our patient, the pattern of liver enzyme elevations suggested a hepatocellular condition. Hepatocellular diseases that may produce jaundice include viral, alcoholic or autoimmune hepatitis, drug or environmental toxicity, hemochromatosis, Wilson's disease, or environmental toxicity, hemochromatosis, or environmental toxicity, hemochromatosis, or environmental toxicity, hemochromatosis, or environmental toxicity, hemochromatosis. Any cause other than the spleen. Both imaging studies were consistent with fatty infiltration of the liver.

The patient's plasma had a turbid appearance. Urinalysis showed marked glycosuria and bilirubinuria.

Hepatitis A immunoglobulin M (IgM) antibody, hepatitis B surface antigen and core IgM antibody, a polymerase chain reaction assay for hepatitis C viral RNA, and serologic tests for Epstein-Barr virus, human immunodeficiency virus, and cytomegalovirus were negative. Tests for anti-nuclear, anti-smooth-muscle, anti-liver-kidney microsomal type 1, anti-mitochondrial, and anti-neutrophil cytoplasmic antibodies were also negative. Levels of α1-antitrypsine and ceruloplasmin were normal, and transferrin saturation was less than 40%.

Abdominal ultrasound examination revealed hepatic enlargement and a diffuse increase in echogenicity of the liver as compared with that of the kidneys (bright liver). No other organ abnormality was observed. An abdominal computed tomography scan (Figure 1), obtained after oral and intravenous administration of contrast material, demonstrated a low-density hepatic parenchyma, which appeared darker than the spleen. Both imaging studies were consistent with fatty infiltration of the liver.

Given the patient's history, physical examination, laboratory results and imaging findings, we concluded the following clinical diagnoses: first, type IV hyperlipoproteinemia, according to Fredrickson's classification4 (familial hypertriglyceridemia), exacerbated by excessive intake of simple carbohydrates, obesity, and insulin resistance, all of which contribute to very-low-density lipoprotein synthesis; second, acute form of NASH. Moreover, the patient met Adult Treatment Panel III criteria for metabolic syndrome.9

The patient was then started on a low calorie diet, with complete exclusion of carbohydrates and fats, and pure intake of high quality protein (chicken breast). He was also treated with isophane insulin (40-30 IU), and omega-3 fatty acids (EPA/DHA 920/760 mg bid). During the next 10 days, the patient showed dramatic improvement of his clinical and laboratory status (Table 1), and was discharged from the hospital. He was advised to keep on the medication received during his hospitalization, reduce calorie intake, eat plenty of vegetables and fruits, rich in fiber and complex carbohydrates with a low glycemic index, avoid saturated fats and simple carbohydrates, walk 30 min every day, quit smoking, and abstain completely from alcohol.

Eight weeks later, the patient was invited for a follow-up appointment. Having strictly implemented medical recommendations, he had lost 20 kg of body weight. His signs and symptoms were entirely resolved. Further, impressive amelioration of laboratory values was noted (Table 1). Continuation of lifestyle modification was emphasized, and isophane insulin dose was reduced by 20% (32-24 IU). Aspirin 100 mg qd, metformin 850 mg bid, pioglitazone 30 mg qd, atorvastatin 20 mg qd, and EPA/DHA 920/760 mg bid were prescribed.

Discussion

Table 1. Laboratory data.

| Variable                  | On admission | After 10 days | After 8 weeks |
|---------------------------|-------------|--------------|--------------|
| Triglycerides (mg/dL)     | >1420       | 478          | 275          |
| Total cholesterol (mg/dL) | >705        | 669          | 213          |
| Total bilirubin (mg/dL)   | 10          | 2.5          | 0.6          |
| Aspartate transaminase (u/L) | 474      | 89           | 22           |
| Alanine transaminase (u/L) | 647       | 165          | 27           |
| C-reactive protein (mg/L) | 43          | 8            | 2.7          |
| Glycosylated hemoglobin (%) | 11.1      | -            | 6.7          |

Figure 1. Abdominal computed tomography scan, obtained after oral and intravenous administration of contrast material, shows a low-density hepatic parenchyma, which appears darker than the spleen. This finding is consistent with fatty infiltration of the liver.

[page 44] [Clinics and Practice 2013; 3:e17]
subacute liver failure (over a period of 4–16 weeks).\textsuperscript{19} In the acute phase of steatohepatitis and subsequent elevation of aminotransferase levels >3 times the upper limit of normal, administration of oral antihyperglycemic agents, or lipid-lowering drugs, such as fibrates or statins, was contraindicated. After normalization of transaminases, our patient was started on a triple antidiabetic treatment, with insulin, metformin, and pioglitazone. Metformin and pioglitazone reduce insulin resistance, which is the pathogenetic basis of metabolic syndrome. Pioglitazone, additionally, has a beneficial effect on NAFLD, improving not only simple steatosis, but also inflammation and fibrosis. Atorvastatin was chosen to reduce low-density lipoprotein-cholesterol (LDL), and omega-3 fatty acids to treat remaining mild hypertriglyceridemia. Both atorvastatin and omega-3 fatty acids have been found to improve simple steatosis. While lifestyle intervention constitutes the cornerstone of NAFLD therapy, the utility of weight loss medications remains controversial. Orlistat confers no additional histological benefit, whereas rimonabant reverses steatosis, but has been withdrawn due to concern about psychiatric adverse effects.\textsuperscript{20}

**Conclusions**

Unhealthy diet, by exacerbating preexisting metabolic disorders, can lead to immediate life-threatening situations. In the context of extreme metabolic dysregulation, NAFLD may present as an acute steatohepatitis.

**References**

1. Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010;24:695-708.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
3. Bellantoni S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010;28:155-61.
4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23.
5. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part I: the metabolic movers. J Gastroenterol Hepatol 2010;25:672-90.
6. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araújo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 2012;49:89-96.
7. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011;33:525-40.
8. Fredrickson DS, Lees RS. A system for phenotyping hyperlipoproteinemia. Circulation 1965;31:321-7.
9. Grundy SM, Cleeman Ji, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735.
10. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;27:412-21.
11. Shimada M, Kawahara H, Ozaki K, et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007;102:1931-8.
12. Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008;103:1372-9.
13. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokinin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009;50:1072-8.
14. Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract 2011;26:565-76.
15. Cowin GJ, Jonsson JR, Bauer JD, et al. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging 2008;28:937-45.
16. Dourakis SP, Sebastianos VA, Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol 2002;97:1074-5.
17. Hofstee HM, Nanayakkara PW, Stehouwer CD. Acute hepatitis related to prednisolone therapy. Eur J Intern Med 2005;16:209-10.
18. Nanki T, Koike R, Miyasaka N. Subacute steatohepatitis during prednisolone therapy. Am J Gastroenterol 2002;97:1074-5.
19. Caldwell SH, Haspenheide EE. Subacute liver failure in obese women. Am J Gastroenterol 2002;97:2058-62.
20. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904.